Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Intragenic Variations in BTLA Gene Influence mRNA Expression of BTLA Gene in Chronic Lymphocytic Leukemia Patients and Confer Susceptibility to Chronic Lymphocytic Leukemia.
Karabon L, Partyka A, Jasek M, Lech-Maranda E, Grzybowska-Izydorczyk O, Bojarska-Junak A, Pawlak-Adamska E, Tomkiewicz A, Robak T, Rolinski J, Frydecka I. Karabon L, et al. Arch Immunol Ther Exp (Warsz). 2016 Dec;64(Suppl 1):137-145. doi: 10.1007/s00005-016-0430-x. Epub 2016 Dec 8. Arch Immunol Ther Exp (Warsz). 2016. PMID: 27933341 Free PMC article.
CD38 gene polymorphisms contribute to genetic susceptibility to B-cell chronic lymphocytic leukemia: evidence from two case-control studies in Polish Caucasians.
Jamroziak K, Szemraj Z, Grzybowska-Izydorczyk O, Szemraj J, Bieniasz M, Cebula B, Giannopoulos K, Balcerczak E, Jesionek-Kupnicka D, Kowal M, Kostyra A, Calbecka M, Wawrzyniak E, Mirowski M, Kordek R, Robak T. Jamroziak K, et al. Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):945-53. doi: 10.1158/1055-9965.EPI-08-0683. Epub 2009 Feb 24. Cancer Epidemiol Biomarkers Prev. 2009. PMID: 19240243
Serum tumor necrosis factor-α and interleukin-10 levels as markers to predict outcome of patients with chronic lymphocytic leukemia in different risk groups defined by the IGHV mutation status.
Lech-Maranda E, Grzybowska-Izydorczyk O, Wyka K, Mlynarski W, Borowiec M, Antosik K, Cebula-Obrzut B, Makuch-Lasica H, Nowak G, Klimkiewicz-Wojciechowska G, Wawrzyniak E, Bilinski P, Robak T, Warzocha K. Lech-Maranda E, et al. Arch Immunol Ther Exp (Warsz). 2012 Dec;60(6):477-86. doi: 10.1007/s00005-012-0197-7. Epub 2012 Sep 4. Arch Immunol Ther Exp (Warsz). 2012. PMID: 22945689 Free article.
29 results